REG - Physiomics PLC - Trading update

PhysiomicsAnnouncement

07/07/2022 07:17

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220707:nRSG5881Ra&default-theme=true

RNS Number : 5881R  Physiomics PLC  07 July 2022

7 July 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Trading update

 

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict
the effects of cancer treatment regimens for the biopharma industry, today
announces that its total income and profit after tax for the financial year
ended 30 June 2022 is likely to be in-line with market expectations.

During the year the Company made planned investments in the hiring of three
new staff members (two technical and the new Head of Business Development)
which contributed to net cash outflows of £356k.  Despite this, the
Company's cash position remains strong, with £687k at the bank as at 30 June
2022, representing almost two years of cash runway.  The Directors expect
that the hiring of these key staff will translate to increased revenues during
the financial year ending 30 June 2023.

The Company is pleased to reflect that over the course of the financial year
ended 30 June 2022 it signed new or follow-on business with Merck KGaA, Numab
Therapeutics, Bicycle Therapeutics, Ankyra Therapeutics, Ducentis
Biotherapeutics and French big pharma company, Servier.  In addition, the
Company has progressed its observational clinical trial in Portsmouth,
designed to generate data to further validate and develop its personalised
dosing software.

Dr Jim Millen, CEO, will deliver a short presentation on this update via the
Investor Meet Company platform on 13 July 2022 at 12pm GMT. The presentation
is open to all existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9:00am the day
before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and "add to meet"
PHYSIOMICS PLC via the following link:
https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://www.investormeetcompany.com/physiomics-plc/register-investor) .
Investors who already follow PHYSIOMICS PLC on the Investor Meet Company
platform will automatically be invited.

 

This announcement is released by Physiomics plc and contains inside
information for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 (MAR), and is disclosed in accordance with the Company's obligations
under Article 17 of MAR.

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEAKXKEFFAEFA